arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MANNKIND CORP

MNKD
$3.35 ▼ -0.13 (-3.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
85 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Bullish
auto_awesome

Analytical Summary

MANNKIND CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.0B
Dividend Yield —
Revenue Growth 42.9% ↗
Op. Margin -0.3% ↗
ROIC -0.1% ↗
FCF / Share $-0.08 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -4.75
info Valuation on last close. End-of-day price, Sep 23, 2026.

85-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$109.37M
↑ +42.9% —
Net Income Profit after all expenses
$-16.62M
— 0.0% —
Operating Margin Operating profit as % of sales
-0.3%
↑ +82.7% 59th
FCF / Share Free cash flow per share
$-0.08
↓ -222.7% —
Long-Term Debt Long-term obligations
$319.08M
— +0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
45
Returns
33
Financial Health ↓
82
Cash Quality ↑
89

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 35 years · 85 quarters